Treprostinil Prodrugs Transdermal Patch Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) often require invasive administration methods, such as intravenous or intramuscular routes, which are uncomfortable and less effective, and there is a need for improved formulations and methods to increase the systemic availability of treprostinil, a key medication for these conditions.
Innovation Solution
Development of novel compounds and compositions, including transdermal delivery systems, represented by specific chemical formulas (Formulas I, II, III, and IV), that enhance the bioavailability and delivery profile of treprostinil and its analogs, allowing for safer and more effective administration through the skin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous or intramuscular administration is used, then the drug can be delivered effectively, but the patient experiences discomfort and potential local trauma
Solution Approach 1:
The patent uses a transdermal delivery system as an intermediary between the drug (treprostinil) and the patient's body. This system includes a patch with a reservoir, rate-controlling membrane, and adhesive layer that mediates drug delivery through the skin, avoiding direct needle insertion while maintaining effective drug delivery to systemic circulation
Solution Approach 2:
The patent employs a flexible transdermal patch with thin film structures including a rate-controlling membrane and adhesive layers. This flexible shell design allows the drug to be delivered through the skin in a controlled manner, eliminating the need for invasive injection while ensuring reliable drug delivery
2Ease of operation
If oral administration is used, then the administration is less invasive, but the systemic availability of treprostinil is insufficient
Solution Approach 1:
The transdermal patch acts as an intermediary delivery system that bypasses the gastrointestinal tract's limitations. By delivering the drug directly through the skin into systemic circulation, the system achieves both the convenience of non-orally-administered drugs and the reliable systemic availability that oral administration cannot provide
Solution Approach 2:
The patent replaces the oral gastrointestinal absorption mechanism with a transdermal delivery mechanism. This substitution uses controlled diffusion through a rate-controlling membrane and passive diffusion through the skin, eliminating the first-pass metabolism and absorption variability associated with oral administration while maintaining ease of use
3Object-affected harmful factors
If transdermal delivery system is developed, then the administration safety is improved, but the device complexity increases
Solution Approach 1:
The transdermal delivery system is segmented into distinct functional layers: a reservoir containing the drug, a rate-controlling membrane that regulates drug release, and an adhesive layer that secures the patch to the skin. This segmentation allows each component to be optimized independently for its specific function, improving safety while managing complexity through modular design
Solution Approach 2:
The transdermal patch is designed as a multi-functional device that combines drug storage, controlled release, skin adhesion, and protective functions in a single unit. This universality improves administration safety by integrating multiple safety features while presenting a simple single-piece device to the user, effectively masking the underlying complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed transdermal delivery system provides improved bioavailability and a safer administration method for treprostinil, potentially offering better treatment options for PH and PAH with reduced discomfort and increased efficacy.
Implementation Method 1
transdermal delivery system which is intended to deliver treprostinil or its derivatives
Data Source
AI summary
Prodrugs of treprostinil are provided which can be used in the treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.